The immunoglobulin M response to rubella vaccine in young adult women.
Rubella vaccination histories were taken from 333 young women working in the head office of a retail organization: 29% said they had had vaccine and 47% said they had not. The remainder did not know. Forty-six per cent of those less than or equal to 25 years old (who should have been offered vaccine at school), and 6% of those greater than 25 years old, said they had been vaccinated. When screened for immunity to rubella by radial haemolysis (RH) 3% had a low level of antibody (less than 15 i.u./ml) and 11% had no antibody. After immunization with Cendevax the specific rubella IgM response was measured by an IgM antibody capture radioimmunassay (MACRIA). It was only detectable in the group without RH antibody, and was present in 26/31 of them. The IgM response to Cendevax was strongest in specimens taken 20-39 days after immunization, but in 10 out of 11 cases tested was still present at around 71 days. The specific IgM responses to Cendevax were very similar to those in women given Almevax in an earlier study, when measured in parallel tests. Taking both vaccines together, specific IgM was present in 35 out of 36 vaccinees without pre-existing antibody tested between 40 and 77 days post-immunization. Detection of specific IgM by MACRIA would therefore be an effective means of determining susceptibility retrospectively in rubella vaccinees found to be pregnant.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis*; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006462:Hemolytic Plaque Technique; D006801:Humans; D007109:Immunity; D007075:Immunoglobulin M / Q000032:analysis / Q000096:biosynthesis*; D011863:Radioimmunoassay; D012409:Rubella / Q000276:immunology*; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D012411:Rubella Vaccine